Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia

被引:21
|
作者
Shustik, C. [1 ]
Bence-Bruckler, I. [2 ]
Delage, R. [3 ]
Owen, C. J. [4 ]
Toze, C. L. [5 ,6 ]
Coutre, S. [7 ]
机构
[1] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[2] Ottawa Hosp, Dept Hematol, Ottawa, ON, Canada
[3] CHU Quebec Univ Laval, Dept Hematol, Quebec City, PQ, Canada
[4] Univ Calgary, Div Hematol & Hematol Malignancies, Calgary, AB, Canada
[5] BC Canc Agcy, Vancouver Gen Hosp, Div Hematol, Leukemia BMT Program BC, Vancouver, BC, Canada
[6] Univ British Columbia, Vancouver, BC, Canada
[7] Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA
关键词
CLL; HSCT; Ibrutinib; Idelalisib; Venetoclax; STEM-CELL TRANSPLANTATION; PREVIOUSLY UNTREATED PATIENTS; TERM-FOLLOW-UP; OPEN-LABEL; INITIAL THERAPY; TREATMENT-NAIVE; ADVERSE EVENTS; FREE SURVIVAL; IBRUTINIB; RITUXIMAB;
D O I
10.1007/s00277-017-2982-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treatment of chronic lymphocytic leukemia (CLL) has advanced with the introduction of chemoimmunotherapy (CIT) agents that have improved the outcomes of frontline therapy. However, most treated patients will relapse and require subsequent therapy. This review focuses on recent advances in the treatment of relapsed or refractory CLL. Until recently, treatment options for relapsed CLL were of limited efficacy. Retreatment with fludarabine, cyclophosphamide, and rituximab (FCR) was recommended for patients with a durable response to first-line FCR, although acquired genetic aberrations, impaired marrow reserve, and comorbidities often made this suboptimal therapy for many patients. New options include two agents targeting B cell receptor (BCR) signaling pathways (ibrutinib and idelalisib) and a B cell lymphoma-2 (BCL-2) inhibitor (venetoclax). Allogeneic hematopoietic stem cell transplantation (HSCT) remains a potentially curative option for younger patients with a suitable donor.
引用
收藏
页码:1185 / 1196
页数:12
相关论文
共 50 条
  • [31] Advances in the treatment of chronic lymphocytic leukemia
    Lamanna N.
    Current Hematologic Malignancy Reports, 2006, 1 (1) : 43 - 48
  • [32] Advances in the treatment of chronic lymphocytic leukemia
    Lamanna N.
    Current Oncology Reports, 2005, 7 (5) : 333 - 338
  • [33] Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Seymour, J. F.
    Kipps, T. J.
    Eichhorst, B.
    Hillmen, P.
    D'Rozario, J.
    Assouline, S.
    Owen, C.
    Gerecitano, J.
    Robak, T.
    De la Serna, J.
    Jaeger, U.
    Cartron, G.
    Montillo, M.
    Humerickhouse, R.
    Punnoose, E. A.
    Li, Y.
    Boyer, M.
    Humphrey, K.
    Mobasher, M.
    Kater, A. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12): : 1107 - 1120
  • [34] Lenalidomide active in patients with refractory or relapsed chronic lymphocytic leukemia
    Nature Clinical Practice Oncology, 2007, 4 (3): : 143 - 143
  • [35] Economic burden of relapsed/refractory chronic lymphocytic leukemia.
    Guerin, Annie
    Ray, Saurabh
    Gauthier, Genevieve
    Hsu, Ling-I
    Zhdanava, Maryia
    Heroux, Julie
    Wu, Eric Qiong
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Tuscano, Joseph
    Poh, Christina
    Rosenberg, Aaron
    Jonas, Brian
    Abedi, Mehrdad
    Barisone, Gustavo
    Schwab, Emily
    Lundeberg, Kathleen
    Kaesberg, Paul
    JOURNAL OF HEMATOLOGY, 2020, 9 (03) : 79 - 83
  • [37] Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
    Niemann, Carsten U.
    Levin, Mark-David
    Dubois, Julie
    Kersting, Sabina
    Enggaard, Lisbeth
    Veldhuis, Gerrit J.
    Mous, Rogier
    Mellink, Clemens H. M.
    Dobber, Johan A.
    Poulsen, Christian B.
    Frederiksen, Henrik
    Janssens, Ann
    Schjodt, Ida
    Dompeling, Ellen C.
    Ranti, Juha
    Mattsson, Mattias
    Bellido, Mar
    Tran, Hoa T. T.
    Nasserinejad, Kazem
    Kater, Arnon P.
    BLOOD, 2021, 137 (08) : 1117 - 1120
  • [38] Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia
    Reagan, John L.
    Castillo, Jorge J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (02) : 151 - 160
  • [39] DIRECT COSTS ASSOCIATED WITH THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RELAPSED OR REFRACTORY IN ARGENTINA
    Godar, M. L.
    Chaves, L.
    Touliet, V
    Kanevsky, D.
    VALUE IN HEALTH, 2018, 21 : S449 - S450
  • [40] Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia
    Owen, Carolyn
    Eisinga, Sarah
    Banerji, Versha
    Johnson, Nathalie
    Gerrie, Alina S.
    Aw, Andrew
    Chen, Christine
    Robinson, Sue
    LEUKEMIA RESEARCH, 2023, 133